Immune-Image

Specific imaging of immune cell dynamics using novel tracer strategies

Summary

Immunotherapies, which harness the immune system to fight disease, are revolutionising the treatment of many cancers and inflammatory diseases. However, while these innovative treatments prove life-saving for some patients, others do not respond to immunotherapies at all, and others experience serious side effects. The Immune-Image project aims to pioneer the use of non-invasive imaging technologies to track the activity of immune cells in the body. Ultimately, the project will make it easier to predict how patients will respond to treatment and monitor their progress during treatment.

To do this, the project will develop tracers capable of highlighting specific immune cells in a range of imaging types, including magnetic resonance imaging (MRI), positron emission tomography (PET), optical imaging (OI) and computed tomography (CT). They will also analyse biopsies and blood samples to build up complete immunological profiles of patients and to correlate imaging findings with pathology; this information will contribute to the development of personalised immunotherapies.

Achievements & News

Participants

  Show participants on map
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Antaros Medical AB, Molndal, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris 15, France
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio), Barcelona, Spain
  • Imaginab, Inc, Inglewood Ca, United States
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Lawrencium Legal BV, Amsterdam, Netherlands
  • Novartis Pharma AG, Basel, Switzerland
  • PNO Life Sciences & Health B.V., Rijswijk, Netherlands
  • Pfizer Limited, Sandwich, United Kingdom
  • Stichting Amsterdam Umc, Amsterdam, Netherlands
  • Stichting Lygature, Utrecht, Netherlands
  • Takeda Pharmaceuticals International AG, Glattpark, Switzerland
  • Universitaet Muenster, Muenster, Germany
  • University of Cambridge, Cambridge, United Kingdom
  • Vib Vzw, Zwijnaarde - Gent, Belgium
  • Vrije Universiteit Brussel, Bruxelles / Brussel, Belgium
Third parties
  • Cloudselling BV, Rijswijk, Netherlands

Participants
NameEU funding in €
Academisch Ziekenhuis Groningen2 174 208
Antaros Medical AB250 000
Commissariat A L Energie Atomique Et Aux Energies Alternatives510 000
Eberhard Karls Universitaet Tuebingen1 103 496
European Cancer Patient Coalition (left the project)80 000
Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca514 560
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron (Vhio)433 310
Lawrencium Legal BV400 000
PNO Life Sciences & Health B.V.290 000
Stichting Amsterdam Umc3 361 722
Stichting Lygature450 000
Universitaet Muenster1 930 000
University of Cambridge1 041 875
Vib Vzw885 000
Vrije Universiteit Brussel1 445 829
 
Third parties
NameFunding in €
Cloudselling BV130 000
 
Total Cost15 000 000